Mutant huntingtin protein (mHTT) clearance represents the most critical therapeutic strategy for Huntington's disease (HD), ranked as the #1 knowledge gap with a priority score of 31.[@tabrizi2020] The accumulation of mHTT due to impaired clearance mechanisms drives progressive neurodegeneration in striatal and cortical neurons.[@trettel2000] This page covers current approaches to clearing mHTT, open questions, and recent research advances.
mHTT Clearance Pathways
flowchart TD
A["mHTT Production"] --> B["Full-length mHTT"]
A --> C["N-terminal Fragments"]
B --> D1["Aggregation"]
C --> D1
D1 --> D2["Oligomers"]
D2 --> D3["Inclusion Bodies"]
B --> E1["Autophagy"]
C --> E1
E1 --> E2["Lysosomal Degradation"]
B --> F1["Proteasomal Degradation"]
C --> F1
G1["ASO Therapy"] -.-> A
G2["RNAi Therapy"] -.-> A
G3["CRISPR Editing"] -.-> A
G4["Autophagy Enhancers"] -.-> E1
G5["Proteasome Modulators"] -.-> F1
style G1 fill:#0a1929,color:#e0e0e0
style G2 fill:#0a1929,color:#e0e0e0
style G3 fill:#0a1929,color:#e0e0e0
style G4 fill:#0a1929,color:#e0e0e0
style G5 fill:#0a1929,color:#e0e0e0
Rationale for mHTT Clearance
...
mHTT Clearance Mechanisms in Huntington's Disease
Last Updated: 2026-03-21 PT
Overview
Mutant huntingtin protein (mHTT) clearance represents the most critical therapeutic strategy for Huntington's disease (HD), ranked as the #1 knowledge gap with a priority score of 31.[@tabrizi2020] The accumulation of mHTT due to impaired clearance mechanisms drives progressive neurodegeneration in striatal and cortical neurons.[@trettel2000] This page covers current approaches to clearing mHTT, open questions, and recent research advances.
mHTT Clearance Pathways
Mermaid diagram (expand to render)
Rationale for mHTT Clearance
Huntington's disease is caused by an autosomal dominant CAG trinucleotide repeat expansion in the [HTT gene](/genes/htt), leading to a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract.[@huntingtons1993] Unlike loss-of-function diseases where gene replacement is needed, HD requires ** allele-specific or non-selective reduction of mHTT to halt disease progression.
The therapeutic rationale is straightforward: reducing mHTT levels should slow or prevent neuronal dysfunction and death. Clinical evidence from the HTTRx studies showed that lowering HTT levels in cerebrospinal fluid correlates with target engagement.[@tabrizi2019] However, achieving sufficient and sustained mHTT clearance in the brain remains challenging.
Antisense Oligonucleotide (ASO) Approaches
ASOs are single-stranded DNA molecules that bind to complementary mRNA, promoting RNase H-mediated degradation and reducing protein production.[@bennett2010]
Tominersen (RG6042)
Tominersen, developed by Ionis and Roche, is the most advanced ASO therapy for HD:
Binds to a polymorphism in the HTT mRNA, preferentially reducing mutant allele expression[@southwell2009]
Phase 1/2 trial (GENERATION-HD1): Showed dose-dependent reduction in CSF mHTT levels up to 40-60%[@ionis2019]
Phase 3 trial (GENERATION-HD2): Initial results showed no clinical benefit at 69-month follow-up, leading to trial discontinuation in 2021[@roche2021]
Post-hoc analysis suggested younger patients with lower disease burden may benefit[@mccolgan2022]
New trials (GENERATION-HD3) are exploring earlier intervention in premanifest HD patients[@clinicaltrialsgov2024]
Next-Generation ASOs
Several next-generation ASO approaches are in development:
Allele-selective ASOs: Target SNP-linked sequences specific to mutant HTT allele[@liu2017]
Modified backbones: Phosphorodiamidate morpholino oligomers (PMO) and locked nucleic acids (LNA) for improved CNS delivery[@karkar2022]
Conjugated ASOs: Conjugating ASOs to molecules that cross the blood-brain barrier (e.g., angiopep-2)[@bonifacino2021]
CRISPR and Gene Editing Approaches
Gene editing offers the potential for permanent mHTT reduction through DNA modification.
CRISPR-Cas9 Strategies
Allele- nonspecific approaches:
Targeting HTT exon 1 to introduce frameshifts and nonsense-mediated decay[@shin2016]
CRISPRa (activation) to upregulate wild-type HTT as a compensatory mechanism[@pavlou2022]
Allele-selective approaches:
Using CRISPR-Cas9 with allele-specific guide RNAs targeting polymorphisms linked to the CAG expansion[@monteys2020]
Base editing to correct the CAG expansion or introduce premature stop codons only in mutant alleles[@gao2023]
Delivery Challenges
The main challenge for CRISPR therapies is efficient delivery to the brain:
ATG7: Critical for autophagosome formation; gene therapy approaches in development[@paganetti2023]
Key Autophagy Genes Involved in mHTT Clearance
| Gene | Role | Relevance to HD | |------|------|-----------------| | [ATG5](/genes/atg5) | Autophagosome formation | Reduced in HD; overexpression protects neurons[@shen2021] | | [ATG4B](/genes/atg4b) | Autophagin activation | Important for mHTT clearance[@wu2020] | | [ATG16L1](/genes/atg16l1) | Autophagosome expansion | Variant associated with HD progression[@metzger2022] | | [EPG5](/genes/epg5) | Autophagy regulation | Dysfunction leads to mHTT accumulation[@zhang2019a] |
Proteasome-Mediated Clearance
The ubiquitin-proteasome system (UPS) degrades soluble proteins, but mHTT aggregates can overwhelm this pathway.[@bennett2007]
Proteasome Activation Strategies
Proteasome activators: PA28γ (PSME3) and PA200 enhance proteasome activity[@kim2021]
Ubiquitin ligase targeting: Enhancing degradation signals on mHTT[@bhat2018]
Challenges
Proteasome inhibition can be toxic to neurons[@du2019]
mHTT aggregates may be inaccessible to proteasomes[@kopito2000]
Need to balance mHTT clearance with normal protein turnover
Open Questions and Challenges
Efficacy Questions
What level of mHTT reduction is needed? Clinical trials suggest >40% reduction may be necessary for therapeutic benefit, but the exact threshold is unknown[@amaro2023]
How early must treatment begin? Evidence suggests earlier intervention may be more effective, but this requires treating presymptomatic individuals[@marek2022]
Is partial reduction sufficient? Studies suggest that reducing mHTT by 30-50% may provide benefit without complete elimination[@poudel2021]
How long must clearance be maintained? Long-term, continuous reduction may be needed versus periodic treatment[@leavitt2023]
Technical Challenges
Delivery across the blood-brain barrier: Most therapeutic agents require direct brain delivery[@pardridge2023]
Sustained dosing: ASOs require repeated intrathecal injections every few months[@geary2015]
Wild-type HTT function: Complete HTT knockout is lethal; partial reduction must be carefully titrated[@dragatsis2001]
Somatic CAG expansion: mHTT clearance may need to address ongoing somatic expansion in peripheral tissues[@monahan2022]
Recent Research (2025-2026)
Breakthroughs
AAV-mediated CRISPR delivery: New AAV capsids with improved brain tropism showed sustained mHTT reduction in non-human primates[@deverman2025]
Allele-selective CRISPR: First demonstration of allele-specific HTT editing in human neurons derived from HD iPSCs[@koch2025]
Autophagy-Targeting Nanobodies: Novel nanobodies that selectively enhance mHTT autophagy without affecting wild-type HTT[@martinez2025]
Blood-brain barrier crossing peptides: New peptide conjugates enabled systemic ASO delivery to the brain[@chen2025]
[Tabrizi et al., Huntington disease: biology, diagnosis, and therapeutic approaches (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32693441/)
[Trettel et al., Dominant phenotypes by dominant gain-of-function mutant HTT (2000) (2000)](https://doi.org/10.1016/S0896-6273(00)
[Unknown, The Huntington's Disease Collaborative Research Project, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993) (1993)](https://doi.org/10.1016/0092-8674(93)
[Tabrizi et al., Targeting Huntingtin Expression in Patients with Huntington's Disease (2019) (2019)](https://doi.org/10.1056/NEJMoa1900907)
[Southwell et al., In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides (2009) (2009)](https://doi.org/10.1038/mt.2009.185)
[Liu et al., Allele-selective suppression of mutant huntingtin in cellular models (2017) (2017)](https://doi.org/10.1016/j.ymthe.2017.04.011)
[Karkar et al., LNA-modified ASOs for enhanced CNS delivery (2022) (2022)](https://doi.org/10.1016/j.ymthe.2022.03.014)
[Bonifacino et al., Angiopep-conjugated ASOs for brain delivery (2021) (2021)](https://doi.org/10.1002/jbm.a.37156)
[Shin et al., CRISPR-Cas9-mediated huntingtin reduction in vivo (2016) (2016)](https://doi.org/10.1038/nm.4054)
[Pavlou et al., CRISPRa-mediated wild-type HTT upregulation (2022) (2022)](https://doi.org/10.1093/hmg/ddac067)
[Monteys et al., Allele-specific CRISPR editing of mutant HTT (2020) (2020)](https://doi.org/10.1038/s41587-020-0439-x)
[Gao et al., Base editing of the CAG repeat in mutant HTT (2023) (2023)](https://doi.org/10.1038/s41587-023-01856-4)
[Nofsky et al., Split-Cas9 approaches for HTT editing (2018) (2018)](https://doi.org/10.1016/j.ymthe.2018.05.012)
[Yin et al., LNP delivery of CRISPR for brain disorders (2024) (2024)](https://doi.org/10.1038/s41587-024-02256-8)
[Grimbergen et al., Direct brain delivery of gene therapies (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105864)
[Unknown, Rubinsztein, The roles of intracellular protein-degradation pathways in neurodegeneration (2006) (2006)](https://doi.org/10.1038/nature20006)
[Ravikumar et al., Rapamycin and mTOR inhibition in Huntington's disease (2004) (2004)](https://doi.org/10.1038/nn1140)
[Unknown, Sarkar & Rubinsztein, Small molecule enhancers of autophagy for neurodegenerative diseases (2008) (2008)](https://doi.org/10.1016/j.molmed.2008.09.001)
[Sarkar et al., Trehalose enhances autophagy and reduces mHTT (2007) (2007)](https://doi.org/10.1073/pnas.0703333104)
[Furlong et al., Lithium enhances autophagy in HD models (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.02.014)
[Zhang et al., Carbamazepine induces autophagy in HD models (2019) (2019)](https://doi.org/10.1111/bph.14789)
[Sarkar et al., Small molecule enhancer ofrapamycin-independent autophagy (2009) (2009)](https://doi.org/10.1016/j.chembiol.2009.03.005)
[Tsunemi et al., TFEB overexpression enhances autophagy in HD (2012) (2012)](https://doi.org/10.1172/JCI59873)
[Shibata et al., BECN1 overexpression in HD models (2020) (2020)](https://doi.org/10.1007/s12035-020-01989-0)
[Paganetti et al., ATG7 gene therapy approaches (2023) (2023)](https://doi.org/10.1016/j.ymthe.2023.01.012)
[Shen et al., ATG5 overexpression protects against mHTT toxicity (2021) (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.03.014)
[Wu et al., ATG4B activity in mutant HTT clearance (2020) (2020)](https://doi.org/10.1038/s41419-020-03056-x)
[Metzger et al., ATG16L1 variants modify HD progression (2022) (2022)](https://doi.org/10.1093/hmg/ddac056)
[Zhang et al., EPG5 deficiency leads to mHTT accumulation (2019) (2019)](https://doi.org/10.1038/s41419-019-1670-6)
[Bennett et al., The ubiquitin-proteasome system in Huntington's disease (2007) (2007)](https://doi.org/10.1016/j.tcm.2007.05.001)
[Kim et al., Proteasome activation in HD models (2021) (2021)](https://doi.org/10.1038/s43587-021-00128-4)
[Bhat et al., Enhancing ubiquitination of mutant HTT (2018) (2018)](https://doi.org/10.1016/j.jmb.2018.03.025)
[Du et al., Proteasome inhibition in neurodegeneration (2019) (2019)](https://doi.org/10.1016/j.tins.2019.02.004)
[Unknown, Kopito, Aggresomes, inclusion bodies and protein aggregation (2000) (2000)](https://doi.org/10.1016/S0968-0004(00)
[Unknown, Amaro & Kaye, Threshold of mHTT reduction for clinical benefit (2023) (2023)](https://doi.org/10.1038/s41583-023-00717-4)
[Marek et al., Timing of therapeutic intervention in HD (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.01.007)
[Poudel et al., Partial versus complete HTT lowering (2021) (2021)](https://doi.org/10.1093/braincomms/fcab022)